Afinitor (everolimus) is not recommended as an NHS-funded treatment for a type of advanced breast cancer because it is not good value for money, according to the latest draft guidance from the NICE. NICE is currently assessing everolimus (in combination with exemestane) as a treatment for HER2 negative, hormone-receptor-positive advanced breast cancer for a particular group of post-menopausal women. Despite not recommending the treatment, the draft guidance states that women who are already receiving everolimus should continue with the treatment until they and their doctor thinks it's appropriate to stop. Sir Andrew Dillon, NICE Chief Executive, said â€œWe are disappointed that the evidence for everolimus isn't stronger, especially as we acknowledge that the drug could represent a new way of treating HER2 negative, hormone-receptor-positive advanced breast cancer by restoring a tumour's sensitivity to hormone therapy.”  For more details, go to http://www.nice.org.uk/newsroom/pressreleases/BreastCancerDrugNotCostEffectiveForNHS.jsp